Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Liu, Jingenga | Hu, Yia; * | Hu, Weib | Xie, Xuana | ELA BELLA, Amosa | Fu, Jianhuaa
Affiliations: [a] Department of Thoracic Oncology, Cancer Center, Sun Yat-sen University, Guangzhou, P. R. China | [b] Department of Thoracic Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, P. R. China
Correspondence: [*] Corresponding author. Yi Hu. Tel.: +86 20 87343258; Fax: +86 020 87343392; E-mail: huyi@sysucc.org.cn.
Abstract: Inhibitor of differentiation 1 (Id1) plays a role in cellular differentiation, proliferation, angiogenesis and tumor invasion. In current study, we investigated the expression of Id1 protein in 189 specimens of stage III ESCC by immunohistochemistry. The correlation between Id1 expression and clinicopathological parameters in terms of gender, age, tumor location, differentiation, pathological T stage and pathological N stage was also explored. Immunohistochemical staining showed that Id1 was expressed in all cases (100%). According to ROC curve, we selected 6.33 as the cutoff score. There were 95 cases in high expression group (> 6.33) and 94 cases in low expression group (⩽ 6.33) respectively. The Id1 expression was associated negatively with differentiation, and positively with pathological N stage (P< 0.05, bothly); No significant correlation was observed between Id1 expression and gender, age, tumor location or pathological T stage (P> 0.05). As shown by the Kaplan-Meier curve, the overall survival rate of high expression group was significantly lower than that of low expression group (P< 0.001). The expression of Id1 protein has a close relationship with differentiation degree, pathological N stage and survival in ESCC patients. Id1 could be considered as a prognostic predictor for stage III ESCC patients.
Keywords: Esophageal neoplasm, Id1, immunohistochemistry, lymph node metastasis, prognosis
DOI: 10.3233/DMA-2011-0831
Journal: Cancer Biomarkers, vol. 8, no. 2, pp. 67-72, 2011
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl